Literature DB >> 15842723

Defining standard of care in the developing world: the intersection of international research ethics and health systems analysis.

Adnan A Hyder1, Liza Dawson.   

Abstract

In recent years there has been intense debate regarding the level of medical care provided to 'standard care' control groups in clinical trials in developing countries, particularly when the research sponsors come from wealthier countries. The debate revolves around the issue of how to define a standard of medical care in a country in which many people are not receiving the best methods of medical care available in other settings. In this paper, we argue that additional dimensions of the standard of care have been hitherto neglected, namely, the structure and efficiency of the national health system. The health system affects locally available medical care in two important ways: first, the system may be structured to provide different levels of care at different sites with referral mechanisms to direct patients to the appropriate level of care. Second, inefficiencies in this system may influence what care is available in a particular locale. As a result of these two factors locally available care cannot be equated with a national 'standard'. A reasonable approach is to define the national standard of care as the level of care that ought to be delivered under conditions of appropriate and efficient referral in a national system. This standard is the minimum level of care that ought to be provided to a control group. There may be additional moral arguments for higher levels of care in some circumstances. This health system analysis may be helpful to researchers and ethics committees in designing and reviewing research involving standard care control groups in developing country research.

Entities:  

Keywords:  Analytical Approach; Biomedical and Behavioral Research; Health Care and Public Health

Mesh:

Substances:

Year:  2005        PMID: 15842723     DOI: 10.1111/j.1471-8847.2005.00109.x

Source DB:  PubMed          Journal:  Dev World Bioeth        ISSN: 1471-8731            Impact factor:   2.294


  8 in total

1.  What drives health research in a developing country?

Authors:  Adamson S Muula
Journal:  Croat Med J       Date:  2007-04       Impact factor: 1.351

Review 2.  Responsibilities to plan for ancillary care pose ethical challenges for nutrition research in the community setting.

Authors:  Maria W Merritt; Holly A Taylor
Journal:  J Nutr       Date:  2012-08-29       Impact factor: 4.798

Review 3.  Ethics review of pediatric multi-center drug trials.

Authors:  Allison C Needham; Mufiza Z Kapadia; Martin Offringa
Journal:  Paediatr Drugs       Date:  2015-02       Impact factor: 3.022

4.  Ethical tradeoffs in trial design: case study of an HPV vaccine trial in HIV-infected adolescent girls in lower income settings.

Authors:  J C Lindsey; S K Shah; G K Siberry; P Jean-Philippe; M J Levin
Journal:  Dev World Bioeth       Date:  2013-05-31       Impact factor: 2.294

5.  Controlling healthcare-associated infections in the international research setting.

Authors:  Catherine Godfrey; Christie Villa; Liza Dawson; Susan Swindells; Jeffrey T Schouten
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

6.  Institutional review boards - a mixed blessing.

Authors:  Taimur Saleem; Umair Khalid
Journal:  Int Arch Med       Date:  2011-06-20

7.  Developing the ethics of implementation research in health.

Authors:  Vijayaprasad Gopichandran; Valerie A Luyckx; Nikola Biller-Andorno; Amy Fairchild; Jerome Singh; Nhan Tran; Abha Saxena; Pascal Launois; Andreas Reis; Dermot Maher; Mahnaz Vahedi
Journal:  Implement Sci       Date:  2016-12-09       Impact factor: 7.327

8.  A survey of tuberculosis infection control practices at the NIH/NIAID/DAIDS-supported clinical trial sites in low and middle income countries.

Authors:  Catherine Godfrey; Gail Tauscher; Sally Hunsberger; Melissa Austin; Lesley Scott; Jeffrey T Schouten; Anne F Luetkemeyer; Constance Benson; Robert Coombs; Susan Swindells
Journal:  BMC Infect Dis       Date:  2016-06-10       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.